The Agenda

Agenda – What’s on when

12:00 – 1:00

Registration and Check-in

1:00 – 1:20

Opening Conference Remarks

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

Gustavo Rivero, MD, – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

Eduardo Sotomayor, MD – Executive Director, Tampa General Hospital Cancer Center Institute

1:20 – 2:20

Session: Racial & Ethnic Disparities in Malignant Hematology

Session Chair Introduction

Gustavo Rivero, MD, – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

1:20-1:40

Gene Ontogeny that Explains Inferior Outcomes in African American AML

Ann-Kathrin Eisfeld, MD – Director, Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center 

1:40-2:00

Is AML Different? Comparing Socioeconomic Disparities in Survival Across Aggressive Hematological Malignancies

Lars Hernandez Nielsen, PhDAssistant Professor, Danish Center for Health Services Research, Denmark

2:00-2:20

Panel and Q&A

Gustavo Rivero, MD, – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

Ann-Kathrin Eisfeld, MD – Director, Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center 

Lars Hernandez Nielsen, PhDAssistant Professor, Danish Center for Health Services Research, Denmark

2:20 – 2:30

Coffee Break

2:30 – 4:10

Session: AI/Computational Biology in Hematology

Session Chair Introduction

Aziz Nazha, MDHematologist-Oncologist, Sidney Kimmel Cancer Center, Jefferson Health — Cherry Hill, New Jersey

2:30-2:50

Machine Learning to Prioritize AML Neopeptides and Predict TCR Specificity

Giancarlo Croce, PhD – Postdoctoral Researcher, Computational Cancer Biology, Ludwig Center for Cancer Research – University of Lausanne

2:50-3:10

Artificial Intelligence in Diagnostic Testing Platforms

Maher Albitar, MDFounder; Chief Executive Officer; Chief Medical Officer, Genomic Testing Cooperative

3:10-3:30

The Future of MDS Management: Integrating Artificial Intelligence Into Clinical Practice

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

3:30-3:50

Panel and Q&A

Aziz Nazha, MDHematologist-Oncologist, Sidney Kimmel Cancer Center, Jefferson Health — Cherry Hill, New Jersey

Giancarlo Croce, PhD – Postdoctoral Researcher, Computational Cancer Biology, Ludwig Center for Cancer Research – University of Lausanne

Maher Albitar, MDFounder; Chief Executive Officer; Chief Medical Officer, Genomic Testing Cooperative

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

4:00-4:50

Abstract Session 

Friday – May 8, 2026

7:30-8:10

Registration and Check-in – Light Breakfast

8:00-8:10

Welcome & Housekeeping

Steering Committee

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

8:10 – 10:10

Session: Myeloid

8:10-8:20

Session Chair Introduction

Relapsed/Refractory AML (Menin)

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

8:20-8:40

Targeting the Menin – KMT2A Axis in Acute Leukemia

Eunice Wang, MD –Chief, Leukemia Service & Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center

8:40-9:00

Advancing Combination Therapy: The Role of Triplets in AML

Nicholas James Short, MDAssociate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

9:00-9:20

Molecular Insights and Novel Therapeutic Strategies in Myelodysplastic Syndromes

Hetty E. Carraway, MD, MBA – Professor of Medicine; Member, Immune Oncology Program, Case Comprehensive Cancer Center

9:20-10:00

Panel and Q&A

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

Eunice Wang, MD –Chief, Leukemia Service & Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center

Nicholas James Short, MDAssociate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Hetty E. Carraway, MD, MBA – Professor of Medicine; Member, Immune Oncology Program, Case Comprehensive Cancer Center

10:00 – 10:25

Coffee Break

10:25-12:15 

Session: Lymphoid

10:25-10:35

Session Chair Introduction

Alan Kerr, II, MD, PhD – Hematologist-Oncologist; Physician Scientist, Tampa General Hospital Cancer Institute

10:35-10:55

Advances in Cellular Therapy in DLBCL

Julio Chavez, MD, MS – Senior Associate Consultant, Division of Hematology/Oncology,
Mayo Clinic — Jacksonville, Florida

10:55-11:15

Advanced in T Cell Lymphoma Therapies

Jonathan Moreira, MD – Associate Professor of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University

11:15-11:25

Lymphoid – Case 2 Discussion

11:25-11:45

Lymphoid – Talk 1

Andre Goy, MD –Physician-in-Chief, Oncology Services, Hackensack Meridian Health

11:45-12:15

Panel and Q&A

Alan Kerr, II, MD, PhD – Hematologist-Oncologist; Physician Scientist, Tampa General Hospital Cancer Institute

Julio Chavez, MD, MS – Senior Associate Consultant, Division of Hematology/Oncology,
Mayo Clinic — Jacksonville, Florida

Jonathan Moreira, MD – Associate Professor of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University

Andre Goy, MD –Physician-in-Chief, Oncology Services, Hackensack Meridian Health

12:15-12:45

Lunch / Exhibits

12:45-1:25

Non-CME Session

1:25-1:55

Break / Exhibits

1:55-2:10

Abstract Presentations

2:10-4:00

Session: Myeloma

Session Chair Introduction

Ivan Marques Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

2:10-2:30

Immune Predictors of Responsiveness to CAR-T and Bispecifics in Myeloma

Madhav Dhodapkar, MBBS – Professor, Translational Science & Therapeutics Division, Scientific Director, Multiple Myeloma Program, Milton B. Rubin Family Endowed Chair, Fred Hutchinson Cancer Center

22:30-2:50

Myeloma – Talk 2

Robert Z. Orlowski, MD, PhDDirector, Myeloma Section, The University of Texas MD Anderson Cancer Center

2:50-3:10

Myeloma – Talk 3

Ankit Kansagra, MDHematologist-Oncologist, Physician Scientist, Tampa General Hospital Cancer Institute

3:10-3:20

Myleoma – Case 1 Discussion

Jennifer Hanle, MSN, AGPCNP-BCNurse Practitioner, Multiple Myeloma, Bone Marrow Transplant and Cell Therapy Programs, Tampa General Hospital Cancer Institute

3:20-3:30

Myleoma – Case 2 Discussion

Ivan Marques Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

3:30-4:00

Panel Dicussion and Q&A

Ivan Marques Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

Madhav Dhodapkar, MBBS – Professor, Translational Science & Therapeutics Division, Scientific Director, Multiple Myeloma Program, Milton B. Rubin Family Endowed Chair, Fred Hutchinson Cancer Center

Robert Z. Orlowski, MD, PhDDirector, Myeloma Section, The University of Texas MD Anderson Cancer Center

Ankit Kansagra, MDHematologist-Oncologist, Physician Scientist, Tampa General Hospital Cancer Institute

Jennifer Hanle, MSN, AGPCNP-BCNurse Practitioner, Multiple Myeloma, Bone Marrow Transplant and Cell Therapy Programs, Tampa General Hospital Cancer Institute

4:00

Final Remarks

REGISTRATION
OPEN

SPONSOR

Interested In sponsoring the event? Email Bonnie Duggan by using the link below!

Tampa General Hospital